A Case Report of Asenapine Augmentation of Clozapine in Resistant Bipolar Type I. - 09/06/15
Résumé |
Introduction and purpose of the study |
Asenapine is an atypical antipsychotic indicated for the treatment of schizophrenia and of the manic or mixed episodes in bipolar I disorder [1]. The different therapeutics option like mood stabilizers and atypical antipsychotics are used to better treat the single episode but also to stabilize manic/depressive cyclicity [2]. The aim of this case report is to underline a possible augmentation of asenapine to clozapine.
Method |
’Mrs. T.P.’, is a caucasian woman aged 45 suffering from bipolar disorder type I followed by mixed depressive phases with subsequent short free period. The patient was treated with different typical and atypical antipsychotics, combined with mood stabilizers, with a partial response. With lithium 900 mg/day, valproate 1500 mg/day and clozapine 250 mg/day showed a partial improvement and remission of the symptoms. To that point we introduced asenapine 20 mg/day with rapid clinical improvement without major side effects. After 1 year the patient is still showing a good affective stability, with an improvemnt of metabolic and without cognitive side effects.
Discussion and conclusions |
Our case report underlines the possibility of asenapine augmentation of clozapine in bipolar I disorder therapy resistant manic patients [3]. Asenapine can increase the plasmatic levels of clozapine, exhibits a unique effect and his pharmacodynamic characteristics may mediate its symptom relief in positive, negative and mood symptoms. Further research is warranted to replicate our clinical observation.
Le texte complet de cet article est disponible en PDF.Vol 30 - N° S1
P. 1142 - mars 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?